D 7003

Drug Profile

D 7003

Latest Information Update: 17 Oct 2008

Price : $50

At a glance

  • Originator Draco Lakemedel
  • Class Antibronchitics; Expectorants
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bronchitis

Most Recent Events

  • 17 Oct 2008 Removed MoA
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
  • 08 Mar 1996 Discontinued-Clinical for Bronchitis in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top